Affinage

TRAF7

E3 ubiquitin-protein ligase TRAF7 · UniProt Q6Q0C0

Length
670 aa
Mass
74.6 kDa
Annotated
2026-06-10
51 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TRAF7 is a RING finger–containing E3 ubiquitin ligase that integrates protein-degradation control with scaffold-based signal transduction to regulate inflammatory signaling, endothelial homeostasis, and cellular growth (PMID:15001576, PMID:21518757). Through its RING domain and a conserved catalytic cysteine, TRAF7 catalyzes ubiquitination of multiple substrates: it drives K48-linked polyubiquitination and proteasomal degradation of TBK1 (dampening IRF3/IFN-β antiviral responses) (PMID:37086853), of the circadian transcription factor DBP in concert with the E2 enzymes UBE2G1/UBE2T to set circadian period (PMID:39379486), and of tumor-suppressive or developmental transcription factors p53, KLF4, and SOX12 in cancer cells (PMID:31730901, PMID:34775479, PMID:40623321); it also promotes K29-linked ubiquitination of NEMO and p65/RelA, routing them to lysosomal degradation to repress NF-κB (PMID:21518757, PMID:20948544). Its seven WD40 repeats mediate protein interactions—most notably with the MAP3Ks MEKK2 and MEKK3 (PMID:15001576, PMID:38814079)—placing TRAF7 upstream in the fluid shear stress–responsive MEKK3–MEK5–ERK5–KLF2 endothelial axis together with SCRIB, where its loss is embryonic lethal from impaired endothelial integrity (PMID:37583551). TRAF7 additionally supports endothelial barrier function via Robo4 and VE-cadherin stabilization (PMID:30510113, PMID:38479633) and negatively regulates c-Myb by promoting its sumoylation and cytoplasmic sequestration (PMID:16162816). Somatic loss-of-function mutations that disrupt catalysis or RAS-GTPase interaction activate CDC42/RAS signaling and drive meningioma and other tumors (PMID:34215617), while dominant-negative germline mutations act through heterodimerization with wild-type protein and disrupt TRAF7–IFT57-dependent ciliogenesis, causing a developmental syndrome (PMID:37043537).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 2004 High

    Established TRAF7 as a domain-defined TRAF family member and linked it functionally to MAP3K signaling, answering what kind of protein it is and what pathway it engages.

    Evidence Co-IP, antisense depletion, domain mapping, and reporter assays showing MEKK3-dependent AP1/CHOP activation and apoptosis induction

    PMID:15001576

    Open questions at the time
    • Did not establish ubiquitin ligase substrates
    • Apoptosis mechanism not resolved at the substrate level
  2. 2005 High

    Showed TRAF7 acts as a transcriptional repressor of c-Myb through stimulation of sumoylation and cytoplasmic sequestration, and confirmed intrinsic E3 ligase activity via self-ubiquitination.

    Evidence Co-IP/domain mapping, in vitro sumoylation assay with site mutants, reporter assays, and subcellular fractionation

    PMID:16162816

    Open questions at the time
    • Mechanism by which TRAF7 stimulates sumoylation unclear
    • Physiological context of c-Myb regulation not defined
  3. 2005 Medium

    Placed TRAF7 in TLR2-driven innate signaling alongside TRAF6 with CYLD as a negative regulator, broadening its role beyond MEKK3.

    Evidence Overexpression/reporter epistasis for NF-κB and p38 with TLR2 ligand stimulation

    PMID:16230348

    Open questions at the time
    • Reliance on overexpression rather than endogenous loss-of-function
    • Direct CYLD-TRAF7 deubiquitination not shown biochemically
  4. 2010 High

    Identified TRAF7 as a direct MyoD1 transcriptional target controlling NF-κB during myogenesis and identified NEMO as a TRAF7 interactor whose ubiquitylation depends on TRAF7.

    Evidence ChIP, siRNA depletion with differentiation assays, proteomic Co-IP screen, and ubiquitylation assays in myoblasts

    PMID:20948544

    Open questions at the time
    • Ubiquitin linkage type on NEMO not specified here
    • Generality beyond muscle context unknown
  5. 2011 High

    Defined a mechanism for TRAF7-mediated NF-κB repression via K29-linked ubiquitination and lysosomal degradation of NEMO and p65.

    Evidence Reciprocal Co-IP, K29-linkage-specific ubiquitination, lysosomal inhibitor rescue, and transcriptomic analysis

    PMID:21518757

    Open questions at the time
    • Atypical K29 linkage mechanism not structurally explained
    • In vivo relevance of lysosomal routing not tested
  6. 2017 Medium

    Linked tumor-associated WD40-domain mutations to gain of aberrant NF-κB activation, connecting genotype to a signaling output.

    Evidence WT vs mutant expression with p-NF-κB/L1CAM Westerns and IHC in adenomatoid tumors

    PMID:29148537

    Open questions at the time
    • Single in vitro system
    • Mechanism connecting WD40 mutation to NF-κB activation not resolved
  7. 2018 Low

    Indicated TRAF7 normally promotes ERK1/2 signaling, since germline syndrome mutations reduce ERK1/2 phosphorylation.

    Evidence In vitro expression of patient-derived mutants with phospho-ERK1/2 Western blot

    PMID:29961569

    Open questions at the time
    • Single phospho-Western readout without mechanistic follow-up
    • No endogenous or in vivo confirmation
    • Relationship to ERK5 axis unclear
  8. 2019 Medium

    Extended TRAF7 substrate range to KLF4 in cancer, coupling its ligase activity to pro-metastatic motility.

    Evidence Co-IP, ubiquitination assay, KLF4 rescue, and migration/invasion assays in vitro and in vivo

    PMID:31730901

    Open questions at the time
    • Ubiquitin linkage on KLF4 not specified in this study
    • Single tumor type
  9. 2019 High

    Showed TRAF7 is required for Robo4-mediated protection of endothelial barrier integrity, establishing a vascular function.

    Evidence Reciprocal binding, deletion mapping, gain/loss-of-function, and Robo4 knockout mouse endotoxemia model

    PMID:30510113

    Open questions at the time
    • Whether TRAF7 ligase activity is required downstream of Robo4 not resolved
    • Direct effector of VE-cadherin stabilization not identified
  10. 2021 High

    Defined TRAF7 as a proteostatic regulator of RAS-related GTPases whose loss drives CDC42/RAS signaling and meningeal cell transformation, mechanistically explaining tumorigenic mutations.

    Evidence Ubiquitinome/proteome/interactome analysis, primary meningeal cell transformation model, and genetic epistasis with KLF4

    PMID:34215617

    Open questions at the time
    • Direct GTPase ubiquitination substrate(s) not fully enumerated
    • How mutations selectively impair RAS interaction not structurally defined
  11. 2021 Medium

    Confirmed TRAF7 acts upstream of MEKK3 in NF-κB/MAPK signaling in brain, with loss conferring neuroprotection after injury.

    Evidence Brain-specific conditional knockout, Co-IP, MEKK3 overexpression rescue, and OGD/R neuron-glia models

    PMID:34953447

    Open questions at the time
    • Single lab
    • Role of ligase activity vs scaffold function in this context unclear
  12. 2021 Medium

    Identified p53 as a TRAF7 K48-ubiquitination substrate, explaining a route to its pro-tumorigenic activity in HCC.

    Evidence Co-IP, K48-specific ubiquitination assay, and p53-dependent rescue with phenotype assays

    PMID:34775479

    Open questions at the time
    • Single tumor system
    • Relationship to KLF4 degradation in same cells not integrated
  13. 2023 High

    Demonstrated RING- and C131-dependent K48 ubiquitination of TBK1 by TRAF7, defining a negative regulatory node in antiviral IFN signaling.

    Evidence Co-IP, K48-specific ubiquitination, RING/C131 mutagenesis, knockout cells, and IRF3/IFN-β assays

    PMID:37086853

    Open questions at the time
    • In vivo antiviral relevance not tested
    • Regulation of TRAF7 activity during infection unknown
  14. 2023 High

    Established TRAF7 as essential for endothelial integrity through the shear stress–responsive MEKK3–MEK5–ERK5–KLF2 axis, mapping SCRIB and MEKK3 to distinct TRAF7 regions.

    Evidence Conditional knockout mice with embryonic lethality, domain-specific Co-IP mapping, and shear stress assays with ERK5/KLF2 readouts

    PMID:37583551

    Open questions at the time
    • Whether ubiquitin ligase activity is required for ERK5 activation unresolved
    • Order of SCRIB/MEKK3 assembly on TRAF7 not defined
  15. 2023 High

    Explained the genetic mechanism of TRAF7-associated developmental syndrome and tumors through dominant-negative heterodimerization and disrupted IFT57-dependent ciliogenesis.

    Evidence Heterodimerization assay, TRAF7-IFT57 Co-IP, primary culture cilia assay, and morpholino knockdown in Xenopus and zebrafish

    PMID:37043537

    Open questions at the time
    • Mechanism connecting IFT57 binding to cilia maintenance not detailed
    • Whether ciliary defects underlie all syndrome features unknown
  16. 2024 High

    Identified TRAF7 as the E3 ligase, with UBE2G1/UBE2T, that controls DBP turnover and circadian period, extending its substrate repertoire to clock regulation.

    Evidence Proteomic interactome, E2 dominant-negative screen, Co-IP of the TRAF7-E2-DBP complex, K48 ubiquitination, and circadian period assay in knockout cells

    PMID:39379486

    Open questions at the time
    • How TRAF7 activity is gated by time of day unknown
    • Physiological circadian phenotype in vivo not tested
  17. 2024 High

    Showed that H2S-driven S-sulfhydration of TRAF7 at Cys327 inhibits KLF4 ubiquitination, defining a redox switch that stabilizes the endothelial barrier.

    Evidence S-sulfhydration assay, Co-IP, ubiquitination assay, Cys327 mutagenesis, and endothelial permeability/VE-cadherin assays

    PMID:38479633

    Open questions at the time
    • Endogenous source/dynamics of H2S modification in vivo not established
    • Interplay with C131 catalytic cysteine unclear
  18. 2024 Medium

    Confirmed MEKK2 and MEKK3 as endogenous WD40-binding partners of TRAF7 by showing a pathogen effector displaces them, validating the scaffold interface.

    Evidence Co-affinity purification, proteomics, confocal imaging, and domain deletion mapping in Chlamydia infection

    PMID:38814079

    Open questions at the time
    • Functional consequence of MEKK displacement on host signaling not quantified
    • Single pathogen system
  19. 2025 Medium

    Added SOX12 as a K48-ubiquitination substrate of TRAF7 with tumor-suppressive consequences in esophageal squamous cell carcinoma.

    Evidence Co-IP, K48-specific ubiquitination, and SOX12-dependent rescue with proliferation/migration assays

    PMID:40623321

    Open questions at the time
    • Single lab with limited orthogonal validation
    • Tissue-specificity of substrate choice unexplained

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how TRAF7 selects among its diverse substrates and switches between scaffold (MEKK2/3-ERK5) and catalytic (degradative) modes across tissues.
  • No structural model of substrate recognition by the WD40/RING architecture
  • Regulation of ubiquitin linkage choice (K48 vs K29) not mechanistically explained
  • Tissue-specific determinants of substrate preference unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0016874 ligase activity 4 GO:0098772 molecular function regulator activity 3 GO:0060090 molecular adaptor activity 2
Localization
GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-1266738 Developmental Biology 2 R-HSA-1643685 Disease 2 R-HSA-9909396 Circadian clock 1
Partners
IFT57IKBKGMAP3K2MAP3K3RELAROBO4SCRIBTBK1

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 TRAF7 was identified as a novel TRAF family member containing a RING finger domain, zinc finger domain, and seven WD40 repeats. It specifically interacted with MEKK3 and potentiated MEKK3-mediated AP1 and CHOP activation; depletion by antisense RNA inhibited this activation. Overexpression induced caspase-dependent apoptosis. Domain mapping showed TRAF7 uses distinct domains for MEKK3 signaling versus apoptosis induction. Co-immunoprecipitation, antisense RNA depletion, overexpression with reporter assays, domain mapping, caspase activity assays The Journal of biological chemistry High 15001576
2005 TRAF7 binds to the DNA-binding domain of c-Myb via its WD40 repeats and stimulates sumoylation of c-Myb at Lys-523 and Lys-499 (same sites as PIASy-induced sumoylation). TRAF7 has E3 ubiquitin ligase activity for self-ubiquitination. TRAF7 inhibited c-Myb-induced transactivation dependent on sumoylation sites. Overexpressed TRAF7 localizes to the cytoplasm and sequesters c-Myb and SUMO1 there, thereby negatively regulating c-Myb activity. Co-immunoprecipitation, domain mapping, sumoylation assay, transcriptional reporter assay, immunofluorescence/subcellular fractionation, mutagenesis of sumoylation sites Molecular biology of the cell High 16162816
2005 Activation of TLR2 signaling induces activation of IKKs-IκBα and MKK3/6-p38 pathways not only through TRAF6 but also through TRAF7. CYLD tumor suppressor acts as a negative regulator of both TRAF6 and TRAF7, likely via a deubiquitination-dependent mechanism, forming an autoregulatory feedback loop controlling NF-κB-dependent inflammatory responses. Overexpression, reporter assays for NF-κB and p38 activation, TLR2 ligand stimulation (PGN, MALP-2, Pam3CSK4), cytokine measurement The Journal of biological chemistry Medium 16230348
2011 TRAF7 physically associates with NEMO (IKKγ) and p65/RelA. TRAF7 promotes Lys-29-linked polyubiquitination of both NEMO and p65, leading to their lysosomal degradation and repression of NF-κB transcriptional activity. TRAF7 also influences p65 nuclear distribution and promotes cell death. Co-immunoprecipitation, ubiquitination assays with K29-linkage-specific analysis, lysosomal inhibitor experiments, microarray expression analysis, cell death assays The Journal of biological chemistry High 21518757
2010 Traf7 is a direct transcriptional target of MyoD1 in muscle cells. Traf7 depletion accelerates myogenesis partly through downregulation of NF-κB activity. NEMO was identified as a Traf7-interacting protein by proteomic screen, and ubiquitylation of NEMO is regulated exclusively by Traf7 activity in myoblasts, coupling MyoD1 function to NF-κB activity. ChIP (MyoD1 binding to Traf7 promoter), siRNA depletion with myogenic differentiation assays, proteomic/co-IP screen identifying NEMO, ubiquitylation assays in myoblasts EMBO reports High 20948544
2017 Expression of mutant (but not wild-type) TRAF7 in vitro led to increased phosphorylation of NF-κB and increased expression of L1CAM, a marker of NF-κB pathway activation, demonstrating that adenomatoid tumor-associated TRAF7 WD40 domain mutations drive aberrant NF-κB pathway activation. In vitro expression of wild-type vs. mutant TRAF7, Western blot for p-NF-κB and L1CAM, immunohistochemistry Modern pathology Medium 29148537
2019 TRAF7 interacts with KLF4 protein via its N-terminus and promotes ubiquitin-mediated proteasomal degradation of KLF4, thereby promoting HCC cell migration and invasion. Restoration of KLF4 abrogated TRAF7-induced cell motility. Co-immunoprecipitation, ubiquitination assay, KLF4 overexpression rescue, migration/invasion assays in vitro and in vivo Cancer letters Medium 31730901
2019 Robo4 binds to TRAF7 through interaction with the C-terminus of Robo4 in endothelial cells. TRAF7 is required for Robo4-mediated suppression of TNFα-induced vascular hyperpermeability and stabilization of VE-cadherin at cell junctions. Loss of TRAF7 abrogates Robo4's protective function, and Robo4-/- mice show increased vascular leakage and mortality in endotoxemia. Co-immunoprecipitation, deletion assays, gain- and loss-of-function studies, Robo4 knockout mouse endotoxemia model, permeability assays, VE-cadherin localization Journal of cell science High 30510113
2021 TRAF7 loss-of-function mutations disrupt either its catalytic E3 ligase activity or its interaction with RAS GTPases. TRAF7 acts as a proteostatic regulator of RAS-related small GTPases; TRAF7 loss in meningeal cells alters actin dynamics and promotes anchorage-independent growth by inducing CDC42 and RAS signaling. KLF4 loss of function disrupts a negative feedback loop (TRAF7-loss-driven RAS/MAPK pathway activates KLF4-dependent transcription of the Semaphorin pathway) and enhances TRAF7 mutant-mediated cell transformation. TRAF7 ubiquitinome and proteome analysis, interactome mapping, in vitro meningioma model from primary meningeal cells, genetic epistasis, actin dynamics assays, anchorage-independent growth assays Cancer research High 34215617
2021 TRAF7 directly interacted with MEKK3 in neuronal/glial cells. Brain-specific TRAF7 deletion ameliorated neuronal death and neuroinflammation after TBI. MEKK3 overexpression abrogated the protective effects of TRAF7 knockout, establishing TRAF7 upstream of MEKK3 in NF-κB and MAPK signaling in brain. Brain-specific conditional knockout mice, Co-immunoprecipitation of TRAF7-MEKK3, MEKK3 overexpression rescue, primary cortical neuron/glial OGD/R model, cytokine measurement, NF-κB/MAPK pathway analysis International immunopharmacology Medium 34953447
2021 TRAF7 promotes ubiquitin-proteasome-mediated degradation of p53 at K48 site in hepatocellular carcinoma cells. Physical interaction between TRAF7 and p53 was identified. TRAF7's pro-tumorigenic functions (inhibiting apoptosis, promoting proliferation/invasion) depended on p53 in rescue assays. Co-immunoprecipitation, ubiquitination assay specifying K48-linkage, rescue assays with p53, overexpression/knockdown with cell phenotype assays Cell death discovery Medium 34775479
2023 TRAF7 interacts with TBK1 and promotes K48-linked polyubiquitination and proteasomal degradation of TBK1 through its RING domain, impairing IRF3 activation and IFN-β production. The conserved cysteine at position 131 of TRAF7 is necessary for this function. TRAF7 knockout facilitated IRF3 activation and increased antiviral gene transcription. Co-immunoprecipitation, K48-specific ubiquitination assay, TRAF7 RING domain mutagenesis (C131 mutation), TRAF7 knockout cells, IRF3 activation assays, IFN-β reporter assay Virologica Sinica High 37086853
2023 Targeted deletion of TRAF7 in mice is embryonic lethal due to impaired endothelium integrity, similar to Mekk3-, Mek5- or Erk5-deficient mice, with significantly lower expression of KLF2 downstream of MEKK3-MEK5-ERK5. TRAF7 associates with SCRIB (planar cell polarity protein) via its N-terminal region, while MEKK3 associates with the C-terminal WD40 domain. SCRIB and TRAF7 together mediate fluid shear stress-induced ERK5 phosphorylation in endothelial cells. Conditional knockout mouse (embryonic and endothelial-specific), Co-immunoprecipitation domain mapping of TRAF7-SCRIB and TRAF7-MEKK3, shear stress assays in cultured endothelial cells, ERK5/KLF2 Western blotting iScience High 37583551
2023 TRAF7 mutants (associated with meningioma/congenital heart defects) operate in a dominant-negative manner by heterodimerizing with wild-type TRAF7 protein. Somatic and inherited TRAF7 mutations disrupt TRAF7-IFT57 interactions, leading to cilia degradation. TRAF7 knockdown in Xenopus and zebrafish caused cardiac, craniofacial, and ciliary defects. TRAF7-mutant meningioma primary cultures lack cilia. Heterodimerization assay (dominant-negative mechanism), Co-IP of TRAF7-IFT57, primary culture ciliogenesis assay, TRAF7 morpholino knockdown in Xenopus and zebrafish Proceedings of the National Academy of Sciences of the United States of America High 37043537
2024 TRAF7 is an E3 ligase that forms a complex with E2 enzymes UBE2G1 and/or UBE2T to promote K48-linked polyubiquitination and proteasomal degradation of the circadian transcription factor DBP. TRAF7 knockout in NIH3T3 cells impairs time-of-day-dependent regulation of DBP levels, and TRAF7 overexpression shortens the circadian period. Proteomic analysis of DBP-interacting proteins, dominant-negative E2 screen (19 variants), Co-IP of TRAF7-UBE2G1/UBE2T-DBP complex, K48-specific ubiquitination assay, TRAF7 knockout in NIH3T3, circadian period assay Communications biology High 39379486
2024 TRAF7 interacts with KLF4 and promotes its ubiquitin-mediated degradation. H2S S-sulfhydrates TRAF7 at Cys327, which weakens the TRAF7-KLF4 interaction and reduces ubiquitination of KLF4, thereby stabilizing KLF4 and upregulating VE-cadherin to protect endothelial barrier integrity. A TRAF7-Cys327 mutant mimicking S-sulfhydration recapitulated these protective effects. S-sulfhydration assay, Co-immunoprecipitation, ubiquitination assay, TRAF7-Cys327 mutagenesis, VE-cadherin expression/localization, endothelial permeability assay Free radical biology & medicine High 38479633
2024 The C. trachomatis effector Tri1 specifically interacts with TRAF7 during infection, recruits TRAF7 to the Chlamydia inclusion, and displaces native TRAF7 binding partners MEKK2 and MEKK3. The Tri1 coiled-coil domain is necessary for interaction with the TRAF7 WD40 domain. These findings confirm MEKK2 and MEKK3 as endogenous TRAF7 WD40-binding partners. Co-affinity purification, immunofluorescence confocal imaging, proteomics, domain deletion assays, infection-based interaction studies Microbiology spectrum Medium 38814079
2025 TRAF7 interacts with SOX12 protein and promotes K48-linked ubiquitination-mediated proteasomal degradation of SOX12 in esophageal squamous cell carcinoma cells. TRAF7's inhibitory effects on tumor cell proliferation and migration partly depended on SOX12, as shown by rescue experiments. Co-immunoprecipitation, K48-specific ubiquitination assay, rescue assay with SOX12 overexpression, cell proliferation and migration assays Biochemistry and cell biology Medium 40623321
2018 In vitro analyses of de novo germline TRAF7 missense mutations found in patients with developmental delay and congenital anomalies showed reduced ERK1/2 phosphorylation, indicating that TRAF7 promotes ERK1/2 signaling under normal conditions. In vitro expression of patient-derived TRAF7 mutants, Western blot for ERK1/2 phosphorylation American journal of human genetics Low 29961569

Source papers

Stage 0 corpus · 51 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (New York, N.Y.) 721 23348505
2013 Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta neuropathologica 201 23404370
2005 The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. The Journal of biological chemistry 171 16230348
2004 TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. The Journal of biological chemistry 147 15001576
2012 The seventh ring: exploring TRAF7 functions. Journal of cellular physiology 90 22105767
2017 Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 79 29148537
2018 Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 77 30171198
2011 TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation. The Journal of biological chemistry 76 21518757
2017 The Emerging Role of TRAF7 in Tumor Development. Journal of cellular physiology 71 27808423
2017 Genomic analysis reveals frequent TRAF7 mutations in intraneural perineuriomas. Annals of neurology 59 28019650
2005 TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation. Molecular biology of the cell 51 16162816
2018 De Novo Missense Variants in TRAF7 Cause Developmental Delay, Congenital Anomalies, and Dysmorphic Features. American journal of human genetics 47 29961569
2014 MicroRNA-126 attenuates palmitate-induced apoptosis by targeting TRAF7 in HUVECs. Molecular and cellular biochemistry 36 25318608
2020 Phenotypic spectrum and transcriptomic profile associated with germline variants in TRAF7. Genetics in medicine : official journal of the American College of Medical Genetics 33 32376980
2019 TRAF7 enhances ubiquitin-degradation of KLF4 to promote hepatocellular carcinoma progression. Cancer letters 33 31730901
2019 Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta neuropathologica communications 30 31470906
2021 Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-Like GTPase Signaling and Promote Meningioma Development. Cancer research 28 34215617
2019 The Robo4-TRAF7 complex suppresses endothelial hyperpermeability in inflammation. Journal of cell science 27 30510113
2010 Traf7, a MyoD1 transcriptional target, regulates nuclear factor-κB activity during myogenesis. EMBO reports 24 20948544
2018 MicroRNA-126 attenuates cell apoptosis by targeting TRAF7 in acute myeloid leukemia cells. Biochemistry and cell biology = Biochimie et biologie cellulaire 22 29940130
2021 TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma. Human pathology 21 33667423
2021 TRAF7 contributes to tumor progression by promoting ubiquitin-proteasome mediated degradation of P53 in hepatocellular carcinoma. Cell death discovery 20 34775479
2023 Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease. Proceedings of the National Academy of Sciences of the United States of America 15 37043537
2023 TRAF7 is an essential regulator of blood vessel integrity during mouse embryonic and neonatal development. iScience 14 37583551
2023 TRAF7 negatively regulates the RLR signaling pathway by facilitating the K48-linked ubiquitination of TBK1. Virologica Sinica 13 37086853
2011 The first homolog of a TRAF7 (TNF receptor-associated factor 7) gene in a mollusk, Crassostrea hongkongensis. Fish & shellfish immunology 13 21872663
2024 Expression of Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) Candidate Genes EDA2R, PCDH9, and TRAF7 in Normal Human Kidney Development and CAKUT. Genes 12 38927638
2023 TRAF7 inhibits glycolysis to potentiate growth inhibition and apoptosis of myeloid leukemia cells via regulating the KLF2-PFKFB3 axis. Molecular and cellular probes 11 37003349
2024 Hydrogen sulfide improves endothelial barrier function by modulating the ubiquitination degradation of KLF4 through TRAF7 S-sulfhydration in diabetic aorta. Free radical biology & medicine 10 38479633
2021 Long non-coding RNA NEAT1 regulates endothelial functions in subclinical hypothyroidism through miR-126/TRAF7 pathway. Human cell 10 33677813
2023 TRAF7-targeted HOXA5 acts as a tumor suppressor in prostate cancer progression and stemness via transcriptionally activating SPRY2 and regulating MEK/ERK signaling. Cell death discovery 9 37845209
2021 Case Report: Blepharophimosis and Ptosis as Leading Dysmorphic Features of Rare Congenital Malformation Syndrome With Developmental Delay - New Cases With TRAF7 Variants. Frontiers in medicine 8 34513876
2025 TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence. Journal of experimental & clinical cancer research : CR 7 40181456
2025 Review of the Role of TRAF7 in Brain Endothelial Integrity and Cerebrovascular Aging. Life (Basel, Switzerland) 7 40868928
2022 TRAF7-mutated Fibromyxoid Spindle Cell Tumors Are Associated With an Aggressive Clinical Course and Harbor an Undifferentiated Sarcoma Methylation Signature: A Molecular and Clinicopathologic Study of 3 Cases. The American journal of surgical pathology 7 36395468
2021 Brain-specific TRAF7 deletion ameliorates traumatic brain injury by suppressing MEKK3-regulated glial inflammation and neuronal death. International immunopharmacology 6 34953447
2023 Propofol inhibits cell apoptosis and inflammatory response in ox-LDL-induced human umbilical vein endothelial cells through the modulation of the circ_0003645/miR-149-3p/TRAF7 axis. Clinical hemorheology and microcirculation 5 36463437
2021 Multi-suture craniosynostosis in c.1570C>T (p.Arg524Trp) mutated TRAF7: a case report. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 5 34247275
2025 Spatial and Temporal Expression Patterns of EDA2R, PCDH9, and TRAF7 in Yotari (Dab1) Mice: Implicationsfor Understanding CAKUT Pathogenesis. International journal of molecular sciences 4 40650197
2024 Expanding the Phenotypic Spectrum of TRAF7-Related Cardiac, Facial, and Digital Anomalies With Developmental Delay: Report of 11 New Cases and Literature Review. Pediatric neurology 3 38569228
2024 TRAF7 determines circadian period through ubiquitination and degradation of DBP. Communications biology 3 39379486
2022 TRAF7 somatic mosaicism in a patient with bilateral optic nerve sheath meningiomas: illustrative case. Journal of neurosurgery. Case lessons 3 35733823
2025 TRAF7-Mutated Myxoid and Spindle Cell Mesenchymal Tumor Occurring in a Pediatric Patient in the Post-Transplant Setting: Expanding the Spectrum of TRAF7-Mutated Tumors. Genes, chromosomes & cancer 2 41229068
2025 TRAF7 in signaling and disease: emerging mechanisms and clinical implications. Molecular medicine (Cambridge, Mass.) 2 41372821
2024 The Chlamydia trachomatis Inc Tri1 interacts with TRAF7 to displace native TRAF7 interacting partners. Microbiology spectrum 1 38814079
2024 cba-miR-222-3p involved in photoperiod-induced apoptosis in testes of striped hamsters by targeting TRAF7. Integrative zoology 1 39466916
2026 TRAF7-Mutated Fibromyxoid Spindle Cell Tumor of Bone: An Osseous Case Expanding the Spectrum of TRAF7-Mutated Tumors With Over 20 Years Clinical Follow-Up. Genes, chromosomes & cancer 0 41811066
2025 TRAF7 inhibits proliferation and migration of esophageal squamous cell carcinoma by ubiquitination-mediated degradation of SOX12. Biochemistry and cell biology = Biochimie et biologie cellulaire 0 40623321
2025 Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights. SAGE open medical case reports 0 40761367
2025 Primary TRAF7-Mutated Myxoid Mesenchymal Tumor With Predominant Epithelioid Morphology: Expanding the Morphologic Spectrum of TRAF7-Mutated Myxoid Mesenchymal Tumors. Cureus 0 41608005
2024 The Chlamydia trachomatis Inc Tri1 interacts with TRAF7 to displace native TRAF7 interacting partners. bioRxiv : the preprint server for biology 0 38464023

Missed literature

Know a paper Affinage missed for TRAF7? Flag it for the maintainers and the community.

No submissions yet.